Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive-human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrenceReport as inadecuate




Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive-human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research

, 18:73

First Online: 02 July 2016Received: 01 January 2016Accepted: 17 June 2016DOI: 10.1186-s13058-016-0731-3

Cite this article as: Miyoshi, Y., Shien, T., Ogiya, A. et al. Breast Cancer Res 2016 18: 73. doi:10.1186-s13058-016-0731-3

Abstract

BackgroundThe significance of the expression of aldehyde dehydrogenase 1 ALDH1, a cancer stem cell marker, for predicting the recurrence of estrogen receptor ER-positive-human epidermal growth factor receptor type 2 HER2-negative breast cancer is still poorly understood. The value of ALDH1 in predicting the time of recurrence remains unknown.

MethodsIn total, 184 patients with early distant recurrence, 134 patients with late distant recurrence, and 321 control patients without recurrence for more than 10 years after starting initial treatment for ER-positive-HER2-negative breast cancer, registered in 9 institutions, were analyzed. We assessed relationships between ALDH1 and other clinicopathological features, and ALDH1 expression was compared among the three groups. The relationship between ALDH1 expression and overall survival after recurrence was also evaluated in each group.

ResultsThe rates of ALDH1 expression positivity more than 1 % in the early, late, and no recurrence groups were 18.4 %, 13.4 %, and 8.4 %, respectively. ALDH1 expression correlated significantly with lymph node metastases p = 0.048 and the Ki-67 labeling index p < 0.001 in the early recurrence group. Multivariate analysis revealed ALDH1 expression to be significantly higher in the early recurrence group than in the no recurrence group adjusted OR 2.140, 95 % CI 1.144–4.003, p = 0.016. Moreover, there was a significant difference in ALDH1 expression between the early and no recurrence groups receiving adjuvant endocrine therapy and chemotherapy adjusted OR 4.625, 95 % CI 1.881–12.474, p < 0.001. However, there was no difference in ALDH1 expression between the late and no recurrence groups in univariate analysis OR 1.507, 95 % CI 0.738–2.998, p = 0.253. In multivariate analysis, ALDH1 was not a factor independently predicting overall survival after the detection of recurrence adjusted OR 1.451, 95 % CI 0.985–2.085, p = 0.059.

ConclusionsAmong patients with ER-positive-HER2-negative breast cancer, ALDH1 expression was more common in those with early recurrence, and this expression was found to be associated with a more aggressive breast cancer phenotype than that in the patients without recurrence. Further study is needed to clarify the prognostic significance of the heterogeneity of cancer stem cells and to confirm their role in resistance to chemotherapy.

KeywordsBreast cancer Estrogen receptor-positive Human epidermal growth factor receptor type 2-negative Aldehyde dehydrogenase 1 Time of recurrence  Download fulltext PDF



Author: Yuichiro Miyoshi - Tadahiko Shien - Akiko Ogiya - Naoko Ishida - Kieko Yamazaki - Rie Horii - Yoshiya Horimoto - Norikazu 

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents